Boston Scientific Corporation $BSX Position Boosted by Teacher Retirement System of Texas

Teacher Retirement System of Texas raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 6.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 931,793 shares of the medical equipment provider’s stock after acquiring an additional 60,144 shares during the quarter. Teacher Retirement System of Texas owned approximately 0.06% of Boston Scientific worth $100,084,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Transcend Capital Advisors LLC grew its stake in Boston Scientific by 30.3% during the 2nd quarter. Transcend Capital Advisors LLC now owns 11,347 shares of the medical equipment provider’s stock valued at $1,219,000 after acquiring an additional 2,638 shares in the last quarter. Bessemer Group Inc. grew its stake in Boston Scientific by 14,391.8% during the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after acquiring an additional 2,899,653 shares in the last quarter. Schmidt P J Investment Management Inc. grew its stake in Boston Scientific by 36.9% during the 2nd quarter. Schmidt P J Investment Management Inc. now owns 14,408 shares of the medical equipment provider’s stock valued at $1,548,000 after acquiring an additional 3,887 shares in the last quarter. Brookwood Investment Group LLC purchased a new position in Boston Scientific during the 2nd quarter valued at about $640,000. Finally, Ashton Thomas Private Wealth LLC grew its stake in Boston Scientific by 74.8% during the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 11,607 shares of the medical equipment provider’s stock valued at $1,247,000 after acquiring an additional 4,966 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 170,214 shares of company stock worth $17,548,337 over the last three months. 0.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BSX. Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 24th. BTIG Research reissued a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Wednesday, October 22nd. Canaccord Genuity Group reissued a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Thursday. Morgan Stanley boosted their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Stock Down 1.3%

Shares of Boston Scientific stock opened at $101.08 on Monday. The stock has a market capitalization of $149.78 billion, a P/E ratio of 54.06, a PEG ratio of 2.04 and a beta of 0.61. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a 50 day moving average price of $101.14 and a two-hundred day moving average price of $102.12. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.